Search

A recent study conducted at Brigham and Women's Hospital in Boston, Massachusetts, examined the association between prostate-specific antigen (PSA) screening and prostate cancer outcomes. The study analyzed data from cancer registries in eight US states and found that higher county-level prevalence of PSA screening was associated with lower odds of advanced disease, all-cause mortality, and prostate cancer-specific mortality. The associations varied by age, race and ethnicity, and US Census region. The study suggests that PSA screening may be beneficial for certain high-risk groups. [Extracted from the article]

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2010.03.018 Byline: Charles L. Wiggins (a)(b), Linda C. Harlan (c), Harold E. Nelson (a), Jennifer L. Stevens (d), Cheryl L. Willman (b), Edward N. Libby (b), Robert A. Hromas (b) Keywords: Age discrimination; Chronic myeloid leukemia; Imatinib; Socioeconomic status Abstract: Imatinib is a highly effective treatment for chronic myeloid leukemia. It was approved by the Food and Drug Administration in 2001 and thereafter rapidly became front-line therapy. This study characterized the prevailing chronic myeloid leukemia therapies in the United States and assessed the impact of imatinib on chronic myeloid leukemia survival and mortality rates in the general population. Author Affiliation: (a) New Mexico Tumor Registry, University of New Mexico Health Sciences Center, Albuquerque (b) University of New Mexico Cancer Center, University of New Mexico Health Sciences Center, Albuquerque (c) National Cancer Institute, Bethesda, Md (d) Information Management Systems, Incorporated, Rockville, Md Article Note: (footnote) Funding: The National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the Leukemia and Lymphoma Society supported this study. Dr Wiggins acknowledges the support of NCI Contracts NO1-PC-35138, N01-PC-35133, N01-PC-35135, N01-PC-35141, N01-PC-35136, N01-PC-35137, N01-PC-35139, N01-PC-35142, N01-PC-35143, N01-PC-35145, N01-PC-54402, N01-PC-54404, and N01-PC-54405, and the University of New Mexico Cancer Center, a recipient of NCI Cancer Center Support Grant P30-CA118100. Dr Willman was supported by LLS SCOR 7388-06 and the NCI 5UO1 CA88361, and Dr Hromas was supported by LLS 7388-06, NIH CA139429, NIH CA100862, NIH CA140442, and NIH HL075783., Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript. The content of this article does not necessarily reflect the views or policies of the NCI or the University of New Mexico, nor does the mention of trade names, commercial products, or organizations imply endorsement by the NCI or the University of New Mexico., Authorship: All authors had access to the data and played a role in writing this manuscript.

2021 AUG 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Cancer are discussed in a new report. According to [...]

2020 OCT 8 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Oncology - Cervical Cancer have been presented. According to news reporting [...]

2019 OCT 24 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on breast cancer is the subject of a new report. According to [...]

High rates of cervical cancer were reported in New Mexico in the early 1970s, with especially high rates for minority women. We examined data collected from 1970 to 1987 for invasive cervical cancer and cervical carcinoma in situ for New Mexico's Hispanic, American indian, and non-Hispanic white women to determine whether changes had occurred in cervical cancer rates since earlier reports. To further characterize the epidemiology of cervical cancer in New Mexico, we reviewed state vital statistics for cervical cancer deaths occurring between 1958 and 1987. From 1970 to 1987, the incidence for invasive cervical cancer among Hispanic (18.9 per 100,000 person-years) and American Indian women (22.0 per 100,000 person-years) was about double that for non-Hispanic white women (10.3 per 100,000). The incidence in each ethnic group decreased over time for both invasive cancer and carcinoma in situ when the data were examined by 2 time periods (1970 to 1978 and 1979 to 1987). These decreases were most dramatic for invasive cervical cancer. Cervical cancer-related death rates for Hispanics and non-Hispanic whites also decreased from 1958 to 1987. Although our data reflect declines in cervical cancer rates during the study period, further rate decreases, especially for minority women, remain an important public health goal in New Mexico. (Becker TM, Wheeler CM, Key CR, Samet JM: Cervical cancer incidence and mortality in New Mexico's Hispanics, American Indians, and nonHispanic whites. West J Med 1992 Apr; 156:376-379), Cancer incidence and mortality vary markedly for many sites among the racial and ethnic groups living in the southwestern United States.(1,2) New Mexico's Hispanics, American Indians, and non-Hispanic whites-the three [...]